
Aytu BioPharma, Inc. (AYTU) entered into a merger agreement on November 16, 2026, to be acquired by Rosemont Pharmaceuticals Holdings, Inc. in a deal valued at $16.53 million.
Rosemont would acquire Aytu through a tender offer for $2.70 per share, representing a 48.35% premium over the stock’s last close.
Aytu BioPharma is a specialty pharmaceutical company focused on developing and commercializing prescription medicines for central nervous system (CNS) disorders, including ADHD and major depressive disorder, as well as products for allergy, sleep, cough, and pediatric health conditions. The company primarily operates in the U.S. market, serving patients through its portfolio of branded prescription products.
Rosemont Pharmaceuticals is a UK-based specialty pharmaceutical company engaged in the development, manufacture, and distribution of prescription medicines, specialising in oral liquid formulations across therapeutic areas including gastrointestinal, cardiovascular, and central nervous system disorders. The company has a portfolio of over 130 products, including licensed and unlicensed medicines, and supplies pharmaceutical products across more than 40 international markets.
Rosemont intends to commence the tender offer within 10 business days.
The closing is anticipated to occur in late December 2026.
Aytu’s certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management have signed agreements supporting the tender offer.
Canaccord Genuity acted as financial advisor to Aytu, with Dorsey & Whitney serving as its legal counsel. Rosemont was advised by Bourne Partners as financial advisor and Ropes & Gray as legal counsel.
Rosemont is acquiring Aytu at a multiple of 0.38 times sales.
For comprehensive insights into this merger and acquisition transaction, please visit the Deal Metrics page here:
The Deal Metrics page for each merger or acquisition includes:
Disclaimer: Please do your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article